Hui, A., Li, J., Zhu, L., Tang, R., Ye, H., Lin, M., . . . Zhu, F. (2022). Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. The Lancet regional health. Western Pacific, 29, 100586. https://doi.org/10.1016/j.lanwpc.2022.100586
Chicago-Zitierstil (17. Ausg.)Hui, Ai-Min, et al. "Immunogenicity and Safety of BNT162b2 MRNA Vaccine in Chinese Adults: A Phase 2 Randomised Clinical Trial." The Lancet Regional Health. Western Pacific 29 (2022): 100586. https://doi.org/10.1016/j.lanwpc.2022.100586.
MLA-Zitierstil (9. Ausg.)Hui, Ai-Min, et al. "Immunogenicity and Safety of BNT162b2 MRNA Vaccine in Chinese Adults: A Phase 2 Randomised Clinical Trial." The Lancet Regional Health. Western Pacific, vol. 29, 2022, p. 100586, https://doi.org/10.1016/j.lanwpc.2022.100586.